Niagen Bioscience is trading 5.31% down now at $2.77, with no company-specific announcement or catalyst surfaced for October 1, 2026.

  • A market listing reported no headlines for the company that day.
  • Reuters reported the U.S. 10-year Treasury yield reached a multi-decade high as investors braced for higher interest rates.
  • Major indices in the supplied market context were down less than 0.5%; this backdrop alone does not establish the cause of the stock’s larger decline.